Ligand Pharmaceuticals Incorporated (LGND)vsRegeneron Pharmaceuticals Inc (REGN)
LGND
Ligand Pharmaceuticals Incorporated
$232.55
+0.11%
HEALTHCARE · Cap: $2.76B
REGN
Regeneron Pharmaceuticals Inc
$721.05
+2.67%
HEALTHCARE · Cap: $73.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 5465% more annual revenue ($14.92B vs $268.09M). LGND leads profitability with a 46.4% profit margin vs 29.6%. REGN appears more attractively valued with a PEG of 1.43. LGND earns a higher WallStSmart Score of 71/100 (B).
LGND
Strong Buy71
out of 100
Grade: B
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.7%
Fair Value
$272.20
Current Price
$232.55
$39.65 discount
Margin of Safety
+51.8%
Fair Value
$1456.29
Current Price
$721.05
$735.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 46 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Revenue surging 39.4% year-over-year
Earnings expanding 103.2% YoY
Safe zone — low bankruptcy risk
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.7%
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LGND
The strongest argument for LGND centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 46.4% and operating margin at 33.6%. Revenue growth of 39.4% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Altman Z-Score, Market Cap, Profit Margin. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : LGND
The primary concerns for LGND are PEG Ratio, P/E Ratio.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
LGND carries more volatility with a beta of 1.00 — expect wider price swings.
LGND is growing revenue faster at 39.4% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LGND scores higher overall (71/100 vs 64/100), backed by strong 46.4% margins and 39.4% revenue growth. REGN offers better value entry with a 51.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ligand Pharmaceuticals Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?